{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:28:00Z","timestamp":1788834480719,"version":"build-2803163510"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010391","name":"Tokyo Women's Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.urolonc.2024.04.008","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T21:22:40Z","timestamp":1713820960000},"page":"291.e27-291.e37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma"],"prefix":"10.1016","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5146-656X","authenticated-orcid":false,"given":"Hiroki","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hironori","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.04.008_bib0001","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0002","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0003","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0004","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0005","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0006","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0007","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0008","doi-asserted-by":"crossref","first-page":"2957","DOI":"10.1200\/JCO.22.00868","article-title":"Management of metastatic clear cell renal cell carcinoma: ASCO Guideline","volume":"40","author":"Rathmell","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2021.102157","article-title":"Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?","volume":"94","author":"Guida","year":"2021","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0011","doi-asserted-by":"crossref","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0012","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0013","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","article-title":"Prognostic value of sarcopenia in adults with solid tumors: a meta-analysis and systematic review","volume":"57","author":"Shachar","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0014","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/bjc.2017.149","article-title":"Subcutaneous adiposity is an independent predictor of mortality in cancer patients","volume":"117","author":"Ebadi","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0015","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.clnu.2021.11.014","article-title":"Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement","volume":"41","author":"Donini","year":"2022","journal-title":"Clin Nutr"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0016","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.clgc.2015.07.015","article-title":"Sarcopenia evaluated using the skeletal muscle index is a significant prognostic factor for metastatic urothelial carcinoma","volume":"14","author":"Taguchi","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0017","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1093\/jjco\/hyaa045","article-title":"Prognostic impact of sarcopenia in patients with metastatic hormone-sensitive prostate cancer","volume":"50","author":"Ikeda","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0018","doi-asserted-by":"crossref","first-page":"ii1","DOI":"10.1093\/annonc\/mdx810","article-title":"Sarcopenic obesity: hidden muscle wasting and its impact for survival and complications of cancer therapy","volume":"29","author":"Baracos","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2019.06.020","article-title":"Effects of weight loss and sarcopenia on response to chemotherapy, quality of life, and survival","volume":"67-68","author":"Ryan","year":"2019","journal-title":"Nutrition"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0020","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s11523-016-0430-0","article-title":"Sarcopenia and the modified glasgow prognostic score are significant predictors of survival among patients with metastatic renal cell carcinoma who are receiving first-line sunitinib treatment","volume":"11","author":"Ishihara","year":"2016","journal-title":"Target Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0021","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s11523-018-0600-3","article-title":"Effect of changes in skeletal muscle mass on oncological outcomes during first-line sunitinib therapy for metastatic renal cell carcinoma","volume":"13","author":"Ishihara","year":"2018","journal-title":"Target Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0022","doi-asserted-by":"crossref","first-page":"7587","DOI":"10.1038\/s41598-017-07955-6","article-title":"Early skeletal muscle loss during target therapy is a prognostic biomarker in metastatic renal cell carcinoma patients","volume":"7","author":"Gu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0023","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.suronc.2015.09.002","article-title":"Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy","volume":"24","author":"Grignol","year":"2015","journal-title":"Surg Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0024","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/onco.13922","article-title":"Body composition as an independent predictive and prognostic biomarker in advanced urothelial carcinoma patients treated with immune checkpoint inhibitors","volume":"26","author":"Martini","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0025","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1097\/CAD.0000000000000982","article-title":"Impact of sarcopenia on the efficacy of pembrolizumab in patients with advanced urothelial carcinoma: a preliminary report","volume":"31","author":"Fukushima","year":"2020","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.lungcan.2020.03.003","article-title":"Cachexia - sarcopenia as a determinant of disease control rate and survival in non-small lung cancer patients receiving immune-checkpoint inhibitors","volume":"143","author":"Roch","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0027","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1038\/s41598-019-39120-6","article-title":"Impact of sarcopenia in patients with advanced non-small cell lung cancer treated with PD-1 inhibitors: a preliminary retrospective study","volume":"9","author":"Shiroyama","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0028","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1002\/jcsm.12755","article-title":"Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis","volume":"12","author":"Takenaka","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0029","first-page":"11","article-title":"Synergic prognostic value of 3D CT scan subcutaneous fat and muscle masses for immunotherapy-treated cancer","author":"Decazes","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0030","article-title":"Prognostic impact of sarcopenia on clinical outcomes in malignancies treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Li","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005226","article-title":"Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study","volume":"10","author":"Lee","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0032","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s10147-020-01833-4","article-title":"Association between skeletal muscle loss and the response to nivolumab immunotherapy in advanced gastric cancer patients","volume":"26","author":"Kano","year":"2021","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0033","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1158\/1078-0432.CCR-22-1389","article-title":"Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade","volume":"28","author":"Ged","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0034","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1159\/000520833","article-title":"Body Mass Index, Sarcopenia, and Their Variations in Predicting Outcomes for Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma","volume":"100","author":"Herrmann","year":"2022","journal-title":"Oncology"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0035","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.707050","article-title":"Body Composition Variables as Radiographic Biomarkers of Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Receiving Immune Checkpoint Inhibitors","volume":"11","author":"Martini","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0036","doi-asserted-by":"crossref","first-page":"415","DOI":"10.4111\/icu.20220028","article-title":"Association between sarcopenia based on psoas muscle index and the response to nivolumab in metastatic renal cell carcinoma: A retrospective study","volume":"63","author":"Ueki","year":"2022","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0037","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1007\/s00330-022-09345-7","article-title":"Association of computed tomography-based body composition with survival in metastatic renal cancer patient received immunotherapy: a multicenter, retrospective study","volume":"33","author":"Wang","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0038","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1016\/j.clgc.2023.05.006","article-title":"Relationship between pretreatment body composition and clinical outcomes in patients with metastatic renal cell carcinoma receiving first-line ipilimumab plus nivolumab","volume":"21","author":"McManus","year":"2023","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0039","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s10147-022-02140-w","article-title":"Extreme leanness, lower skeletal muscle quality, and loss of muscle mass during treatment are predictors of poor prognosis in cervical cancer treated with concurrent chemoradiation therapy","volume":"27","author":"Abe","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0040","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1245\/s10434-017-5875-6","article-title":"Adverse effects of low preoperative skeletal muscle mass in patients undergoing gastrectomy for gastric cancer","volume":"24","author":"Sakurai","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0041","doi-asserted-by":"crossref","first-page":"4887","DOI":"10.21873\/anticanres.15994","article-title":"Sarcopenia is an independent prognostic factor for squamous cell carcinoma of the cervix treated with concurrent chemoradiotherapy","volume":"42","author":"Kise","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0042","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.nut.2016.04.003","article-title":"Proposal for new diagnostic criteria for low skeletal muscle mass based on computed tomography imaging in Asian adults","volume":"32","author":"Hamaguchi","year":"2016","journal-title":"Nutrition"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0043","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0044","doi-asserted-by":"crossref","DOI":"10.1016\/j.nut.2021.111345","article-title":"Sarcopenia and prognosis of advanced cancer patients receiving immune checkpoint inhibitors: a comprehensive systematic review and meta-analysis","volume":"90","author":"Deng","year":"2021","journal-title":"Nutrition"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155217","article-title":"A 2022 update on the epidemiology of obesity and a call to action: as its twin COVID-19 pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on","volume":"133","author":"Boutari","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0046","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/s41591-023-02232-8","article-title":"Body composition and lung cancer-associated cachexia in TRACERx","volume":"29","author":"Al-Sawaf","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0047","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0048","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0049","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.clnu.2023.11.029","article-title":"The importance of ethnic-specific cut-offs of low muscle mass for survival prediction in oncology","volume":"43","author":"Taguchi","year":"2023","journal-title":"Clin Nutr"},{"key":"10.1016\/j.urolonc.2024.04.008_bib0051","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.annonc.2019.10.020","article-title":"Inconsistencies in currently used definitions of sarcopenia in oncology","volume":"31","author":"Taguchi","year":"2020","journal-title":"Ann Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004277?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143924004277?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T02:13:37Z","timestamp":1718849617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143924004277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1078143924004277"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of body composition on outcomes of immune checkpoint inhibitor combination therapy in patients with previously untreated advanced renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}